Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.71 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.56 |
| ▸ | UBE2N | P61088 | 1/20 | 0.56 |
| ▸ | ALPI | P09923 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.55 |
| ▸ | XIAP | P98170 | 1/20 | 0.55 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | CPA1 | P15085 | 3/20 | 0.53 |
| ▸ | CPA3 | P15088 | 2/20 | 0.52 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.52 |
| ▸ | CPB1 | P15086 | 1/20 | 0.52 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.52 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.50 |
| ▸ | ACP3 | P15309 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL599399 | 1.00 | EPHX1 (0.71) | EPHX1P4HTMCYP1A2CHRM1UBE2N | |
| SCHEMBL67234 | 1.00 | EPHX1 (0.71) | EPHX1P4HTMCYP1A2CHRM1UBE2N | |
| Hydrochloric Acid SCHEMBL933353 | 0.98 | EPHX1 (0.69) | EPHX1P4HTMCYP1A2CHRM1UBE2N | |
| SCHEMBL5156210 | 0.88 | ESR1 (0.61) | EPHX1P4HTMCYP1A2CHRM1UBE2N | |
| SCHEMBL5161421 | 0.88 | ESR1 (0.61) | EPHX1P4HTMCYP1A2CHRM1UBE2N | |
| SCHEMBL27600068 | 0.87 | EPHX1 (0.71) | EPHX1CYP1A2CHRM1UBE2NALPI | |
| SCHEMBL3370947 | 0.87 | EPHX1 (0.56) | EPHX1P4HTMPTGS1CYP2C19 | |
| SCHEMBL7816162 | 0.87 | CHRM1 (0.61) | EPHX1P4HTMCYP1A2CHRM1UBE2N | |
| SCHEMBL1296553 | 0.87 | EPHX1 (0.56) | EPHX1P4HTMCYP1A2UBE2NPTGS1 | |
| SCHEMBL4153500 | 0.87 | P4HTM (0.56) | EPHX1P4HTMCYP1A2CHRM1UBE2N |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2251316-B1 | METHOD FOR PRODUCING OPTICALLY ACTIVE ESTER AND METHOD FOR PRODUCING OPTICALLY ACTIVE CARBOXYLIC ACID | TOKYO UNIV OF SCIENCE EDUCATIONAL FOUNDATION ADMINISTRATIVE ORGANIZATION (JP) | 2018-02-21 | — | — | EP | disclosed |
| WO-2014016766-A1 | GUANIDINE DERIVATIVES AS TRPC MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2014-01-30 | — | — | WO | disclosed |
| US-20120149718-A1 | Amido Compounds | BROTHERTON-PLEISS CHRISTINE E (US) | 2012-06-14 | — | — | US | disclosed |
| EP-2251316-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE ESTER AND METHOD FOR PRODUCING OPTICALLY ACTIVE CARBOXYLIC ACID | Tokyo University Of Science Educational Foundation Administrative Organization (JP) | 2010-11-17 | — | — | EP | disclosed |
| US-20100234610-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE ESTER AND METHOD FOR PRODUCING OPTICALLY ACTIVE CARBOXYLIC ACID | TOKYO UNIVERSITY OF SCIENCE EDUCATIONAL FOUNDATION ADMINISTRATIVE ORGANIZATION (JP) | 2010-09-16 | — | — | US | disclosed |
| EP-0673911-B1 | Process for producing optically active carboxylic acids and chiral ligands for this purpose | TAKASAGO PERFUMERY CO LTD (JP) | 1999-01-20 | — | — | EP | disclosed |
| US-5646144-A | FOR TREATING DISORDERS IN WHICH SUBSTANCE P PLAYS A PART IN DEVELOPMENT | CIBA-GEIGY CORPORATION (US) | 1997-07-08 | — | — | US | disclosed |
| US-5563295-A | HYDROGENATION OF OLEFINIC CARBOXYLIC ACID USING RUTHENIUM-PHOSPHINE COMPLEX CATALYST | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1996-10-08 | — | — | US | disclosed |
| US-5541195-A | SUBSTANCE P ANTAGONISTS | CIBA-GEIGY CORPORATION (US) | 1996-07-30 | — | — | US | disclosed |
| EP-0673911-A1 | Process for producing optically active carboxylic acids and chiral ligands for this purpose | Takasago International Corporation (JP) | 1995-09-27 | — | — | EP | disclosed |
| EP-0532456-B1 | 1-Acylpiperidine derivatives and their use as substance P antagonists | CIBA GEIGY AG (CH) | 1995-03-29 | — | — | EP | disclosed |
| US-5310743-A | Substance P antagonist | CIBA-GEIGY CORP. (US) | 1994-05-10 | — | — | US | disclosed |
| EP-0532456-A1 | 1-Acylpiperidine derivatives and their use as substance P antagonists | CIBA-GEIGY AG (CH) | 1993-03-17 | — | — | EP | disclosed |
| EP-0272787-B1 | CATALYTIC PRODUCTION OF OPTICALLY ACTIVE CARBOXYLIC ACID | Takasago International Corporation (JP) | 1992-05-06 | — | — | EP | disclosed |
| US-4962230-A | RUTHENIUM-OPTICALLY ACTIVE PHOSPHINE COMPLEX HYDROGENATION CATALYST | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1990-10-09 | — | — | US | disclosed |
| EP-0272787-A2 | Catalytic production of optically active carboxylic acid | Takasago International Corporation (JP) | 1988-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234610-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE ESTER AND METHOD FOR PRODUCING OPTICALLY ACTIVE CARBOXYLIC ACID | ACADM, ADH5, ALDH7A1 | EPHX1 394/4885P4HTM 1126/4885CYP1A2 239/4885 |
| US-20120149718-A1 | Amido Compounds | P2RX7, P2RX3, P2RX2 | EPHX1 1013/4885P4HTM 1467/4885CYP1A2 1264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.